CymaBay Therapeutics Inc. (CBAY)

Market Cap	333.64M
Revenue (ttm)	n/a
Net Income (ttm)	-105.91M
Shares Out	87.80M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	659,091
Open	3.9
Previous Close	3.94
Day's Range	3.87 - 4.02
52-Week Range	1.67 - 4.3
Beta	0.53
Analysts	Buy
Price Target	10.20 (+158.2%)
Earnings Date	Nov 14, 2022

About CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical stu...

• Industry: Pharmaceuticals
• CEO: Sujal Shah
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: CBAY

Analyst Forecast

According to 15 analysts, the average rating for CBAY stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 158.23% from the latest price.

Price Target

$10.2

(158.23% upside)

Analyst Consensus: Buy